KYTX Company Profile and Key Details

NASDAQ : KYTX

Kyverna Therapeutics

$9.49

-1.25-11.64%

At Close 4:00 PM

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Kyverna Therapeutics, Inc. (KYTX) stock declined over -11.64%, trading at $9.49 on NASDAQ, down from the previous close of $10.74. The stock opened at $10.51, fluctuating between $9.31 and $10.72 in the recent session.

Stock Snapshot

10.74

Prev. Close

415.58M

Market Cap

9.31

Day Low

-2.9

P/E Ratio

-3.27

EPS (TTM)

N/A

Cash Flow per Share

10.51

Open

43.79M

Number of Shares

10.72

Day High

51.96%

Free Float in %

N/A

Book Value

1.19M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
May 15, 2026	10.72	10.72	9.31	9.49	1.19M
May 14, 2026	10.72	11.04	10.23	10.74	911.94K
May 13, 2026	10.29	11.15	10.27	10.78	1.84M
May 12, 2026	10.28	10.28	9.75	10.23	612.89K
May 11, 2026	9.37	10.71	9.37	10.34	1.3M
May 08, 2026	9.35	9.39	9.02	9.35	458.95K
May 07, 2026	9.43	9.50	9.10	9.30	428.91K
May 06, 2026	9.35	9.53	9.25	9.47	587.32K
May 05, 2026	9.10	9.38	8.95	9.21	749.29K
May 04, 2026	8.81	9.13	8.72	9.00	892.94K
Apr 30, 2026	8.53	9.15	8.47	8.80	927.97K
Apr 29, 2026	8.60	8.76	8.25	8.40	756.03K
Apr 28, 2026	8.96	9.23	8.58	8.70	865.37K
Apr 27, 2026	9.30	9.69	8.93	8.99	1.11M
Apr 23, 2026	10.17	10.26	8.80	8.95	2.19M
Apr 22, 2026	11.08	11.14	8.65	10.23	6.08M
Apr 21, 2026	11.25	11.25	9.63	9.71	1.26M
Apr 20, 2026	10.19	11.62	10.10	11.25	2.63M
Apr 17, 2026	9.60	10.03	9.55	9.93	916.06K
Apr 16, 2026	9.40	9.58	9.17	9.53	457.45K

Contact Details

Emeryville, CA 94608

United States

https://kyvernatx.com 510 925 2492

About Company

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

Stock Peers

ARGX

-22.81-2.77%

argenx SE$799.32 REGN

-14.62-2.05%

Regeneron Pharmaceuticals, Inc.$698.25 UTHR

-7.21-1.25%

United Therapeutics Corporation$568.58 MDGL

-16.2-3.00%

Madrigal Pharmaceuticals, Inc.$523.69 VRTX

-13.46-2.99%

Vertex Pharmaceuticals Incorporated$436.95 PRAX

-2.94-0.85%

Praxis Precision Medicines, Inc.$342.58 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 KRYS

-10.01-3.16%

Krystal Biotech, Inc.$306.29 ALNY

-6.47-2.20%

Alnylam Pharmaceuticals, Inc.$286.98 ASND

-4.99-2.03%

Ascendis Pharma A/S$240.50

Company Overview

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) closed at $9.49 USD, losing -$1.25 (-11.64%) from the previous close of $10.74. The stock is currently mid-range between its 52-week high and low $2.06 and $13.67. With a market capitalization of about $415.58 million, Kyverna Therapeutics, Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~2.06). Key stats such as the average daily volume over the past year has been around 868.39 thousand shares, in line with its 52-week average. Headquartered in Emeryville, CA, Kyverna Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Warner Biddle, the company employs approximately 112 people and listed since February 09, 2024. Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases.

Technical Performance

KYTX has shown sold momentum, gaining 9.6% over the past week and 36.05% over the past quarter, though year-to-date performance is down -4.04%. Short-term trend indicators are mixed aligned (SMA20 3.49%, SMA50 -3.67%, SMA200 42.13%). The stock’s 14-day RSI is 50.8 (neutral), while the ATR of 0.58 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -40.6% below its high and over 356.18% above its low. Average 10-day trading volume of 897.47 thousand shares is in line with the 3-month average of 872.94 thousand, indicating normal recent market interest.

Valuation Metrics

Kyverna Therapeutics, Inc. trades at a P/E ratio of -3.66, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 2.93 suggesting the stock is closer to book value. The P/FCF stands at -2.75, also below market averages.

Dividend & Fair Value

Kyverna Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $2.15. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Wall Street analysts project EPS growth of 1.16% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 5 Strong Buy ratings, 4 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $33.00 to $10.00. The high target offers 247.73% upside. The low target suggests 5.37% downside. The mean target is $24.44. This offers 157.53% upside. Kyverna Therapeutics, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended May 12, 2026, missed forecasts by -12.0%. The prior quarter beat by -5.33%. Over the last six quarters, Apple has recorded several small beats. These include 1.15% in March 27, 2025.

Shareholding & Insider Activity

Kyverna Therapeutics, Inc. has 43.25 million shares outstanding. The public float is 22.47 million shares, elevated short interest at 6.05% of float. This equals 1.50 million shares. The short ratio is 3.76 days. Institutional investors hold 70.87% of the float. Insiders own 12.03%. GILEAD SCIENCES, INC. holds 4.13 million shares, Westlake BioPartners Opportunity Fund I, L.P. has 869.32 thousand shares and SEIDENBERG BETH C has 869.32 thousand shares. Over the past six months, insider transactions show net buying. They sold 24.00 thousand shares across 1 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Kyverna Therapeutics has not generated any revenue.
On valuation metrics, Kyverna Therapeutics trades at a P/E of -3.66, P/S of 0.00 and P/B of 2.93. The current ratio is 8.15 and quick ratio is 8.15. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -4890.41 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.05, supported by a cash flow-to-debt ratio of -16.82.

Price Forecast & Outlook

Our AI price prediction model suggests that Kyverna Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 17.39%, with price expected at $11.14 by May 28, 2026, within a range of $10.41 to $11.97 3-Month Outlook: Projected rise of 27.19%, reaching $12.07 by August 12, 2026, with a range of $11.85 to $12.28. 1-Year Outlook: Projected gain of 300.21%, with price at $37.98 by May 14, 2027, within a range of $38.66 to $42.29.

Key Takeaways

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) shares are flat -4.04% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Kyverna Therapeutics, Inc. trading at a premium to the broader market with a P/E of -3.66. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $18.42, suggesting 94.1% upside. Our AI forecast model points to short-term strength (17.39% over two weeks), a medium-term rise (27.19% over three months), and a longer-term gain (300.21% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Kyverna Therapeutics, Inc. (KYTX) stock price?

Kyverna Therapeutics, Inc. (NASDAQ: KYTX) stock price is $9.49 in the last trading session. During the trading session, KYTX stock reached the peak price of $10.72 while $9.31 was the lowest point it dropped to. The percentage change in KYTX stock occurred in the recent session was -11.64% while the dollar amount for the price change in KYTX stock was - $1.25.

KYTX's industry and sector of operation?

The NASDAQ listed KYTX is part of Biotechnology industry that operates in the broader Healthcare sector. Kyverna Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of KYTX?

No Data

How KYTX did perform over past 52-week?

KYTX's closing price is 360.68% higher than its 52-week low of $2.06 where as its distance from 52-week high of $13.67 is -30.58%.

How many employees does KYTX have?

Number of KYTX employees currently stands at 112.

Link for KYTX official website?

Official Website of KYTX is: https://kyvernatx.com

How do I contact KYTX?

KYTX could be contacted at phone 510 925 2492 and can also be accessed through its website. KYTX operates from 5980 Horton Street, Emeryville, CA 94608, United States.

How many shares of KYTX are traded daily?

KYTX stock volume for the day was 1.19M shares. The average number of KYTX shares traded daily for last 3 months was 868.39K.

What is the market cap of KYTX currently?

The market value of KYTX currently stands at $415.58M with its latest stock price at $9.49 and 43.79M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	112
Beta	3.35
Sales or Revenue	N/A
5Y Sales Change%	-1%
Fiscal Year Ends	N/A
Sector	Healthcare
Industry	Biotechnology

KYTX Company Profile and Key Details

Kyverna Therapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Shareholding & Insider Activity

Company Overview

Earnings & Analyst Outlook

Dividend & Fair Value

Financial & Profitability Overview

Valuation Metrics

Price Forecast & Outlook

Key Takeaways